Today: 29 June 2026
CNQ stock drops today as Venezuela turmoil dents Canadian Natural Resources shares
5 January 2026
1 min read

CNQ stock drops today as Venezuela turmoil dents Canadian Natural Resources shares

Toronto, Jan 5, 2026, 14:37 (ET) — Regular session

  • CNQ shares fell about 5% in New York; the Toronto listing was down roughly 8% earlier in the session.
  • Investors repriced heavy-crude producers after the U.S. capture of Venezuela’s President Nicolás Maduro.
  • Focus turns to U.S. policy on Venezuelan oil flows and CNQ’s next quarterly results.

Shares of Canadian Natural Resources Limited (CNQ.TO) (CNQ.N) fell 5.2% to $32.53 in New York afternoon trading on Monday as investors weighed the U.S. capture of Venezuelan President Nicolás Maduro. In early Toronto trade, the stock slid about 8% to C$43.33, while Cenovus Energy lost about 8.7% and Suncor fell to C$59.08, according to The Canadian Press.

The Venezuela shock hit on the first full trading day of the year, when positioning is thin and investors often reset sector bets. For Canadian oil sands names, the concern is straightforward: Venezuelan heavy crude competes for the same U.S. refining demand that absorbs much of Canada’s barrels.

U.S. refiners and some oil majors moved the other way as traders focused on what a shift in Venezuelan flows could mean for the Gulf Coast, Reuters reported. “This type of crude aligns well with the configuration of U.S. Gulf Coast refineries,” said Ahmad Assiri, a research strategist at Pepperstone. Reuters

Oil prices also firmed as the market tried to map the supply implications. Brent was up 1.58% at $61.71 a barrel and U.S. West Texas Intermediate gained 1.66% to $58.27 by 12:56 p.m. EDT, Reuters reported, even as President Donald Trump said the U.S. embargo on Venezuelan oil exports would stay in place for now. OPEC+ — the producer group led by Saudi Arabia and Russia — kept output steady on Sunday, and Venezuelan output averaged about 1 million barrels per day last year, Reuters said.

For Canadian producers, the key variable is the “differential,” the discount heavy oil sells at versus lighter benchmarks. Heavy sour crude — denser oil with higher sulfur — typically earns a lower price because it requires more complex refining.

Canadian Natural is a major producer of oil sands and other heavy barrels, so changes in heavy-crude supply can matter as much as moves in headline oil futures. A wider discount squeezes realized prices even when crude benchmarks are rising.

But the downside case hinges on politics and logistics moving faster than the market expects. If Washington tightens enforcement or keeps the embargo intact, and Venezuela cannot quickly restore exports, the heavy-crude discount may not widen for long.

Traders are watching for any explicit shift in U.S. sanctions or carve-outs that would allow more Venezuelan crude to move legally, and for real-time signals in heavy-grade pricing. In the meantime, CNQ tends to trade as a proxy for how investors see North American heavy oil supply shaping up.

Canadian Natural is due to pay a quarterly dividend of C$0.5875 a share on Jan. 6, the company said.

Shan Ahmed Khan is a senior markets reporter at TS2.tech, specializing in stocks, technology and macroeconomic trends. A graduate of the Lahore University of Management Sciences (LUMS), he previously worked in investment research and market analysis. His coverage helps readers understand the key developments influencing global financial markets and emerging industries.

Stock Market Today

  • AbbVie Stock Surges, Boosting Valuation of $10.9 Billion Apogee Acquisition
    June 28, 2026, 6:38 PM EDT. AbbVie Inc. shares climbed 4.2% to a 52-week high of $253.35 on June 26, lifting the company's market value by approximately $65 billion since June 18. This surge is nearly six times the $10.9 billion cash price AbbVie is paying for Apogee Therapeutics. The acquisition, financed through debt, includes Apogee's late-stage IL-13 antibody zumilokibart for atopic dermatitis. Despite a 49% premium paid over Apogee's June 18 close, AbbVie expects a reduced adjusted earnings per share (EPS) in 2026 and 2027, with accretion only anticipated by 2032. Investors appear focused on AbbVie's long-term immunology growth, with key drugs Skyrizi and Rinvoq generating $6.6 billion in Q1 revenue. AbbVie's CEO described the deal as creating significant long-term shareholder value.

Latest articles

IREN Limited (NASDAQ:IREN) slides as Warriors badge faces AI revenue test

IREN Limited (NASDAQ:IREN) slides as Warriors badge faces AI revenue test

29 June 2026
IREN Limited (NASDAQ:IREN) plunged 21.3% to $47.21 over five straight down days despite announcing a record $50M+ annual Warriors jersey deal, as investors focused on the company’s not fully contracted $4.4B target ARR and high short interest at 19.74% of float, with Friday’s close near the lowest analyst target.
Kroger (NYSE:KR) chicken alert puts Private Selection label controls in focus

Kroger (NYSE:KR) chicken alert puts Private Selection label controls in focus

29 June 2026
Kroger (NYSE:KR) faces scrutiny after a USDA alert flagged mislabeled Private Selection Honey Dijon chicken in nine states, but with no confirmed adverse reactions and the product already off shelves, the stock closed Friday at $57.73, down 5 cents; any expansion of affected lots or confirmed cases could alter risk for investors.
Hyperscale Data (GPUS) stock jumps 20% in premarket as insider buying keeps spotlight on the microcap
Previous Story

Hyperscale Data (GPUS) stock jumps 20% in premarket as insider buying keeps spotlight on the microcap

PBF Energy stock stays hot after analyst upgrades flag West Coast fuel squeeze
Next Story

PBF Energy stock stays hot after analyst upgrades flag West Coast fuel squeeze

Go toTop